Wall Street Zen Upgrades Aclarion (NASDAQ:ACON) to Hold

Aclarion (NASDAQ:ACON) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Aclarion Trading Down 6.7%

NASDAQ ACON opened at $3.06 on Friday. Aclarion has a 1-year low of $2.34 and a 1-year high of $15.08. The stock has a 50-day moving average of $3.08 and a 200-day moving average of $5.52. The firm has a market cap of $2.60 million, a PE ratio of -0.18 and a beta of 1.44.

Aclarion (NASDAQ:ACON) last posted its quarterly earnings results on Wednesday, March 18th. The company reported ($2.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.60) by $1.59. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. Aclarion had a negative return on equity of 52.31% and a negative net margin of 9,517.11%. As a group, equities research analysts forecast that Aclarion will post -263.33 earnings per share for the current fiscal year.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.